Address
516 Rue Pierre et Marie Curie
Labège, Haute Garonne
31670, France
Contact
Robin, DUMAS+330782727623
robin.dumas@vibiosphen.com
Website
Download PDF
VIKYNG
VIKYNG is a AI-powered platform to boost preclinical successful outcome of polypeptoids (new class of compound) from drug discovery to lead optimization
Thanks to it’s AI composition VIKING generate innovative new drug candidates more quickly and more effectively than traditionnal methods.
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial stewardship
- Antimicrobial compound/strategy
- Infection prevention
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- AgriFood
- Environmental
- Veterinary
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- UTI
- BSI
- RTI
- GII
- SSTI
- STI
- CNSI
- IAI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
N.A.
Vibiosphen is a company specialized in infectious disease with two activities – R&D development of a preclinical pipeline in AMR thanks to AI.
Preclinical services in infectious diseases – efficacy and safety studies.
